NO303715B1 - Stabilt, vandig apparat - Google Patents

Stabilt, vandig apparat

Info

Publication number
NO303715B1
NO303715B1 NO932517A NO932517A NO303715B1 NO 303715 B1 NO303715 B1 NO 303715B1 NO 932517 A NO932517 A NO 932517A NO 932517 A NO932517 A NO 932517A NO 303715 B1 NO303715 B1 NO 303715B1
Authority
NO
Norway
Prior art keywords
aqueous
stable
relates
compounds
pharmaceutically
Prior art date
Application number
NO932517A
Other languages
English (en)
Norwegian (no)
Other versions
NO932517L (no
NO932517D0 (no
Inventor
Hans Rudolf Mueller
Martin Ulmann
Josef Conti
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eprova Ag filed Critical Eprova Ag
Publication of NO932517D0 publication Critical patent/NO932517D0/no
Publication of NO932517L publication Critical patent/NO932517L/no
Publication of NO303715B1 publication Critical patent/NO303715B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ink Jet (AREA)
  • Ink Jet Recording Methods And Recording Media Thereof (AREA)
NO932517A 1992-07-13 1993-07-09 Stabilt, vandig apparat NO303715B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2192/92A CH684644A5 (de) 1992-07-13 1992-07-13 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.

Publications (3)

Publication Number Publication Date
NO932517D0 NO932517D0 (no) 1993-07-09
NO932517L NO932517L (no) 1994-01-14
NO303715B1 true NO303715B1 (no) 1998-08-24

Family

ID=4228046

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932517A NO303715B1 (no) 1992-07-13 1993-07-09 Stabilt, vandig apparat

Country Status (18)

Country Link
US (1) US5455236A (ko)
EP (1) EP0579996B1 (ko)
JP (1) JP2667354B2 (ko)
KR (1) KR100217788B1 (ko)
CN (1) CN1032901C (ko)
AT (1) ATE121949T1 (ko)
AU (1) AU661591B2 (ko)
CA (1) CA2100126C (ko)
CH (1) CH684644A5 (ko)
DE (1) DE59300176D1 (ko)
DK (1) DK0579996T3 (ko)
ES (1) ES2072163T3 (ko)
FI (1) FI933151A (ko)
HU (2) HU212665B (ko)
NO (1) NO303715B1 (ko)
RU (1) RU2135519C1 (ko)
TW (1) TW379142B (ko)
ZA (1) ZA934907B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1095472C (zh) * 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
DE602005026352D1 (de) * 2004-09-15 2011-03-31 Nipro Corp Wässrige, stabile (6S)-Folinsäurelösung zur Injektion
AU2008222592B2 (en) * 2007-03-02 2013-09-26 Detsamma Investments Pty Ltd Compositions and methods for delivery of anti-cancer agents
CN101235102B (zh) * 2008-02-18 2010-11-03 南昌航空大学 一种叶酸偶联羟丙基壳聚糖纳米微粒的制备方法
CN102000345A (zh) * 2010-11-16 2011-04-06 广西大学 包合态的叶酸/β-环糊精组合物及其制备方法
CN102258788B (zh) * 2011-06-13 2012-11-07 南开大学 一种靶向传递阿霉素抗癌药的组装体及其制备方法
EP2837631A1 (en) 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
RU2537246C1 (ru) * 2013-10-17 2014-12-27 Федеральное государственное бюджетное учреждение "Научный центр клинической и эскпериментальной медицины" Сибирского отделения Российской академии медицинских наук ФГБУ "НЦКЭМ" СО РАМН Способ получения биотинилированного производного окисленного декстрана
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
KR20200041354A (ko) 2017-08-16 2020-04-21 메르크 파텐트 게엠베하 5,10-메틸렌-(6r)-테트라하이드로폴산 및 디카르복시산을 포함하는 안정한 동결건조물
CN112089848A (zh) * 2020-10-27 2020-12-18 浙江诺得药业有限公司 叶酸的环糊精包合物及其制备方法
WO2023237482A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate
WO2023237480A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl
WO2023237485A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid
WO2023237483A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4350659A (en) * 1981-07-30 1982-09-21 Corning Glass Works Stabilization of sensitive biologically active intermediate metabolites such as folic acid derivatives
JPS602775B2 (ja) 1981-08-28 1985-01-23 富士通株式会社 モニタ機能付大規模集積回路及びその製造方法
JPS59175432A (ja) * 1983-03-25 1984-10-04 Yatoron:Kk ジヒドロ葉酸溶液の安定化方法
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
NL8901432A (nl) * 1989-06-06 1991-01-02 Pharmachemie Bv Bij koelkasttemperatuur stabiele waterige folinaatoplossing, alsmede werkwijze ter bereiding daarvan.
CA2021042A1 (en) 1989-07-21 1991-01-22 Fabrizio Marazza Salts of n ,n -methylene-5,6,7,8-tetrahydrofolic acid
ATE126438T1 (de) 1989-08-21 1995-09-15 American Cyanamid Co Stabile injizierbare pharmazeutische formulation mit folinsäure und leukovorinsalze und verfahren.
IT1237509B (it) 1989-10-31 1993-06-08 Magis Farmaceutici Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche
CH680731A5 (ko) * 1990-04-12 1992-10-30 Sapec Fine Chemicals
AU7953291A (en) 1990-05-11 1991-12-10 Goran Carlsson 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US5153309A (en) * 1990-07-27 1992-10-06 The United States Of America As Represented By The Department Of Health And Human Services Process of making tetrahydropteroylpoly-l-glutamic acid derivatives
CH681303A5 (ko) 1991-01-16 1993-02-26 Eprova Ag
AU657986B2 (en) * 1991-06-14 1995-03-30 Pharmacia & Upjohn Company Imidazo(1,5-a)quinoxalines

Also Published As

Publication number Publication date
HU9301990D0 (en) 1993-09-28
TW379142B (en) 2000-01-11
FI933151A0 (fi) 1993-07-09
AU4187093A (en) 1994-01-20
JP2667354B2 (ja) 1997-10-27
RU2135519C1 (ru) 1999-08-27
EP0579996A1 (de) 1994-01-26
JPH0718084A (ja) 1995-01-20
FI933151A (fi) 1994-01-14
CN1081688A (zh) 1994-02-09
CA2100126A1 (en) 1994-01-14
ATE121949T1 (de) 1995-05-15
NO932517L (no) 1994-01-14
KR100217788B1 (ko) 1999-09-01
AU661591B2 (en) 1995-07-27
ES2072163T3 (es) 1995-07-01
KR940002301A (ko) 1994-02-17
CH684644A5 (de) 1994-11-15
NO932517D0 (no) 1993-07-09
HU212665B (en) 1996-09-30
DE59300176D1 (de) 1995-06-08
CA2100126C (en) 1998-05-05
HU211484A9 (en) 1995-11-28
CN1032901C (zh) 1996-10-02
US5455236A (en) 1995-10-03
EP0579996B1 (de) 1995-05-03
HUT65714A (en) 1994-07-28
DK0579996T3 (da) 1995-07-10
ZA934907B (en) 1994-02-09

Similar Documents

Publication Publication Date Title
NO303715B1 (no) Stabilt, vandig apparat
DE69027440D1 (de) Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE3775882D1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
ATE187167T1 (de) Amido-3-pyrazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
DE3688114D1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
DE69325393D1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
ZA904893B (en) Iibeta-aryl-4-estrenes,process for their production as well as their use as pharmaceutical agents
PT86520A (en) Process for preparing 2,4,5-trisubstituted phenol derivatives useful as anti-inflammatory agents
DE59008170D1 (de) Verfahren zur Herstellung mikronisierter bioabbaubarer Partikel.
ATE121409T1 (de) /3-(c16-c18)alkansulfinyl- und sulfonyl-2- methoxymethyl-propyl/-(2-trimethylammonio- ethyl)phosphate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel.
HUT46664A (en) Process for producing new dihydropyridineamide derivatives and pharmaceutical compositions comprising these compounds
IL111580A (en) Use of melatonin derivatives in the preparation of pharmaceutical compositions for use in treating sleep disorders
ATE106887T1 (de) Ester der 10-(1-hydroxy-äthyl)-11-oxo-1- azatricyclo(7.2.0.0(3,8)>undec-2-ene-2- carbonsäure und deren derivate und verfahren zu ihrer herstellung.
ATE137237T1 (de) R-(-)-1-(5-hydroxyhexyl)-3-methyl-7- propylxanthin, verfahren zu dessen herstellung und diese verbindung enthaltende arzneimittel
PT87301A (pt) Process for the preparation of 1,3-dioxanes by products and of pharmaceutical compounds containing them
ATE118004T1 (de) 4-amidino-chroman und 4-amidino-pyrano(3,2- c)pyridinderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
FR2703048B1 (fr) Nouveaux composes n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
HU904582D0 (en) Process for producing amino-oligohydroxi derivatives and pharmaceutical preparatives containing those compounds
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
HUT54682A (en) Process for producing 13-bromine- and 13,14-dibromine-ergoline derivatives and pharmaceutical preparatives containing these compounds
HU9200400D0 (en) Cinurenic acid derivatives, process for producing them and pharmaceutical compositions containing them
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2003